GenSight Biologics Provides Business Update, Sets Results Date; Stock Up

GenSight Biologics, a clinical-stage gene-therapy company targeting retinal neurodegenerative and central nervous system disorders, announced business updates and referenced its half-year financial statement. The supplied article text is incomplete and provides no financial figures, clinical-trial results, or other material details to assess a more specific market impact.